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A human minigastrin-II analog was prepared by conventional methods in solution using N-benzyloxycarbo- 
nyltyrosine O-sulfate as starting material in the synthetic route. Upon removal of the acid-labile protecting 
groups and purification by preparative reversed-phase chromatography the sulfated gastrin peptide was ob- 
tained in satisfactory overall yields as homogeneous material. It was found to be about twice as active as 
the non-sulfated form in stimulating gastric acid secretion and to exhibit a lo-fold higher affinity to gastrin 
receptors of purified parietal cells. 
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1. INTRODUCTION 
The hormone gastrin is known to exhibit both in 
circulation and in tissues of origin a pronounced 
heterogeneity regarding the peptide length and the 
sulfation of the single tyrosine residue present in 
the C-terminal sequence [3]. Extensive com- 
parative studies have been performed on the 
various gastrins in respect to their peptide length 
using mainly synthetic preparations and related 
analogs. Conversely, investigations on the sulfated 
forms were limited by the low amounts of material 
available from natural sources. Attempts to pro- 
duce the sulfated gastrin via direct sulfation of the 
Standard abbreviations as recommended by the IUPAC- 
IUB commission on Biochemical Nomenclature are 
used. For gastrins abbreviations according to [1,2] are 
used, e.g. HG13-II = C-terminal tridecapeptide of 
gastrin sulfated at the tyrosine residue 
phenolic function in synthetic human little-gastrin- 
I with pyridine-SOS failed [4]. As expected, side 
reactions were found to occur to significant extents 
at various reactive groups of the gastrin sequence. 
We have recently proposed a new approach for 
the synthesis of tyrosine O-sulfate-containing pep- 
tides [5,6]. It is based on the direct use of suitable 
derivatives of this amino acid as starting materials 
and it has been successfully applied for the syn- 
thesis of cholecystokinin-related peptides [7,8]. 
This new strategy has now been adopted for the 
elaboration of clean syntheses of sulfated gastrin 
peptides. 
Here, the synthesis of a sulfated gastrin analog, 
i.e. human des-tryptophan-l,norleucine-lZmini- 
gastrin-II, is described. From previous structure- 
function studies it is known that the methionine 
residue of the C-terminal sequence can be replaced 
by leucine or norleucine and the N-terminal tryp- 
tophan residue deleted without any effect on the 
potency of human minigastrin-I [9, lo]. 
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2. MATERIALS AND METHODS 
Amino acid derivatives used in the synthesis 
were prepared according to [1 11. For preparative 
HPLC Jobin-Yvon Prep-10 was used. TLC was 
carried out on HPTLC silica gel 60 plates (Merck) 
and compounds were visualized by chlorine/ 
toluidine and Pauly reagents. 
Acid hydrolyses were performed in 6 M HCl 
containing 2.5% thioglycolic acid at 110°C for 
24 h in evacuated sealed ampoules, and the 
aminopeptidase M digestion in Tris-HCl buffer 
(pH 7.8) at 37°C for 24 h. Amino acid analyses 
were obtained on a Biotronic amino acid analyser 
(model LC 6001). The gas chromatographic 
racemization test on a Chirasil-Val glass capillary 
column was carried out according to Frank et al. 
1121. 
Stimulation of gastric acid secretion was deter- 
mined in anaesthetized rats (-300 g) according to 
the procedure of Gosh and Schild [ 131 modified by 
Pham-Tham-Chi et al. [14]. 
3. RESULTS 
3.1. Synthesis of human des-tryptophan-I, nor- 
leucine-ltminigastrin-II (Nle”-HGI3-II) 
Taking advantage of our previous synthetic 
studies on human minigastrin-I analogs [ lO,lS], 
the synthesis of Nle”-HGl3-II was performed ac- 
cording to the Schwyzer-Wiinsch strategy using the 
fragment condensation procedure. 
Following the synthetic route outlined in scheme 
1 the side chain protected C-terminal tetrapeptide 
amide (10-13) [8] was acylated with Z-Gly-ONSu 
(9) to yield the N”-benzyloxycarbonylpentapeptide 
derivative (9-13a) which in turn was deprotected 
Z-Gly-ONSu (9) + H-Trp-Nle-Asp(OtBu)-Phe-NH2 (10-13) 
1 
Z-Gly-Trp-Nle-Asp(OtBu)_Phe-NH2 (9-13a) 
I 
H2/Pd 
Z-Tyr (S03Ba 
1/2]-OBa1/2 (*], 
+ H-Gly-Trp-Nle-Asp(OtBu]-Phe-NH2 (9-13b] 
DCC/HOBt 
+ 
Z-Tyr(S03Ba,,2)-Gly-Trp-Nle-Asp(OtBu)-Phe-NH2 (8-13a) 
I 
I H2/Pd 
i 
Boc-Leu- Flu(OtBu]] 5-Ala-OH (l-7) + H-Tyr(S03Ba,,2 )-Gly-Trp-Nle-Asp(OtBu)_Phe-NH2(8-13b) 
1 
DCC/HONSu 
Boc-Leu- [Glu(OtBu)] 5-Ala-Ty;(S03Ba,,2 )-Gly-Trp-Nle-Asp(OtBu)-Phe-NH2 (l-13a) 
I 1) 90 8 CF3COOH 
I 
r.t., 60 min 
2) preparative hplc (u-Bondapak C18; 
eluent: C2H50H / 0.1 M NH40Ac, pH 7.0: 16:84] 
H-L~~-(G~u)~ -Ala-Tyr(S03H)-Gly-Trp-Nle-Asp-Phe-NH2 Cl-13b) 
Scheme 1. Synthetic route for Nle”-HG13-II. 
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at the a-amino function by hydrogenolysis over Pd hydrogenolysis led in 80% yield over the two steps 
catalyst for further chain elongation. The tyrosine to the W-deprotected hexapeptide (I&-13b) as key 
O-sulfate residue (8) was then incorporated via intermediate for the final condensation with the 
condensation of the pentapeptide derivative suitably protected N-terminal fragment (l-7) 
(9-13b) with N-benzyloxycarbonyl derivative which was prepared in the usual manner mainly via 
barium salt 161 by means of DCC in the presence ~-hydroxysucci~mide sters: this synthetic step - 
of l-hydroxybenzot~~ole [ 161 as previously via DCC in the presence of ~-hydroxysuccinimide 
reported for the cholecystokinin peptides [6-81. [17] - produced the fully protected tridecapeptide 
Both the high yield and the homogeneity of the derivative hemibarium salt (l-13a) in 75% yield 
resulting hexapeptide derivative hemibarium salt [amino acid analysis of the acid hydrolysate: Asp, 
(8-13a) confirm the usefulness and high stability 1.03 (1); Glu, 4.72 (5); Gly, 1.00 (1); Ala, 0.92 (1); 
of the tyrosine O-sulfate moiety. Subsequent Leu, 0.92 (1); Nle + Tyr, 1.99 (2); Phe, I.04 (1); 
E 
210 
;: 
0 I 8 12 I6 20 2L 28 32 36 LO AL f.8 52 56 60 61 68 72 
I 
I 1 r ( 
0 I 8 12 16 20 24 28 32 36 LO LL 48 52 56 60 6L 68 72 mm 
Fig.1. HPLC of Nle”-HG13-II. (A) Crude product, (B) purified product. Column: p-Bondapak Cl8 (30 x 0.4 cm); 
eluent; acetonitrile/O.l M sodium phosphate buffer (pH 5.4). Linear gradient from 15 to 28% acetonitrile in 80 min; 
flow rate: 1.7 ml/min. 
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Trp, 1.02 (1); peptide content: 91% calcd for Mr = 
2213.21. The integrity of the tyrosine O-sulfate 
moiety was assessed throughout the synthesis by 
IR spectroscopy (Y = 1050 cm-‘) as well as by TLC 
(Pauly test: negative). 
For removal of the acid-labile protecting groups 
compound (l-13a) was exposed to 90% 
trifluoroacetic acid in the presence of 
2-methylindole as scavenger. As expected from 
previous studies [5] partial hydrolysis of the sulfate 
monoester occurred in the range of lo-15% (see 
fig.lA: desulfated Nle”-HG13 at 30 min retention 
time). tert-Butylation of the tryptophan residue 
[ 181 was again found to occur to significant extents 
(fig. 1A: byproducts with higher retention time) 
even in aqueous trifluoroacetic acid. The latter 
conditions were reported to suppress this side reac- 
tion [19]. The crude deprotection product was 
purified on p-Bondapak Cl8 (4 x 40 cm) using 
ethanol/O. 1 M ammonium acetate buffer (pH 7.0) 
(16 : 84, v/v) at a flow rate of 18 ml/min as eluent. 
Upon Millipore filtration and repeated freeze- 
drying from 1% ammonia Nle”-HG13-II (l-13b) 
was obtained in 39% yield (based on compound 
(l-13a) and on the peptide content of 86%); the 
product behaved homogeneously on HPTLC (sol- 
vent systems: n-butanol/acetic acid/pyridine/ 
water, 60:6:20:24 and 60: 6:40:24) and HPLC 
(fig. 1B) and exhibited the expected amino acid 
ratios in the acid hydrolysate [Asp, 1.00 (1); Glu, 
4.83 (5); Gly, 1.00 (1); Ala, 1.00 (1); Leu, 1.01 (1); 
Nle + Tyr, 1.95 (2); Phe, 1.05 (1); Trp, 0.89 (1); 
peptide content: 86% calcd for M, = 1709.81 and 
AP-M digest [Asp, 1.01 (1); Glu, 4.84 (5); Gly, 
1.01 (1); Ala, 1.00 (1); Leu, 1.03 (1); Phe, 1.01 (1); 
Trp, 1.01 (1); Tyr (SO3H), 1.03 (1); Tyr, 0.00 (0); 
Nle, 1.01 (1); recovery: 84.5% for M, = 1709.81. 
The gas chromatographic racemization test ex- 
cludes racemization along the synthesis to greater 
extents (D-Ala 1.5%; D-Leu < 1%; D-Asp 2.4%; 
D-Phe 1.1%; D-Glu 2.2%; D-Tyr 0.9%; D-Trp < 
1%; D-Nle < 1 ‘?‘o); IR(KBr): v = 1050 cm-‘. 
3.2. Biological activities of Nle”-HG13-II 
Stimulation of gastric acid secretion by sulfated 
and non-sulfated Nle”-HGl3 was comparatively 
determined in male rats. The experimental results 
(table 1) indicate for the sulfated gastrin peptide a 
significant enhancement in potency (about twice as 
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Table 1 
Gastric acid secretion in rats (300 g) after bolus i.v. 
injection of gastrin peptides (saline solution) expressed 
in rmol H+/40 min (mean f SD) 
Dose 
(pmolk) 
50 
150 
300 
450 
Response to 
Nle”-HG13-I Nle”-HG13-II 
5.5 + 0.8 11.5 * 4.3 
(n = 12) (n = 4) 
10.9 f 1.0 17.0 * 7.0 
(n = 42) (n = 6) 
15.2 * 1.1 30.0 + 7.6 
(n = 60) (n = 7) 
18.1 f 2.2 n.d. 
(n = 26) 
potent as the non-sulfated gastrin) and even more 
surprisingly, also in efficacy. 
Additionally, Nle”-HG13-I and Nle”-HG13-II 
were tested for their ability to inhibit binding of 
12sI-Leu25-HG17-I to isolated rabbit purified 
parietal cells known to contain high-affinity 
gastrin receptors. The sulfated gastrin peptide ex- 
hibited a IO-fold higher binding affinity in this ex- 
perimental model than the nonsulfated form (the 
detailed experimental work will be reported 
elsewhere). 
4. DISCUSSION 
The few comparative studies reported so far on 
sulfated and non-sulfated human little-gastrin 
seem to indicate that sulfation does not influence 
their effects on gastric parietal cells and central 
neurons nor the clearance rates [1,20-221. Con- 
versely, sulfation of short gastrin-related peptides 
was found to enhance their potency; this fact was 
mainly attributed to an increased resistance to 
metabolic clearance [23]. Our results concerning in 
vivo gastric acid secretion triggered by bolus i.v. 
injection of the sulfated and non-sulfated 
minigastrin analog contrast with the above 
findings and interpretation. The higher potency 
and particularly the efficacy of the hormone upon 
sulfation cannot be attributed only to a lowered 
hepatic uptake and clearance. Sulfation also af- 
fects the affinity of the hormone for the target cells 
in the stomach as was confirmed by competitive in- 
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hibition studies on binding of radiolabeled gastrin 
to parietal cells. These results clearly indicate that 
sulfation of gastrin must play a significant 
biological role. To unravel its physiological impor- 
tance further detailed studies will be performed 
with the synthetic gastrin-II analog. 
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